Synthaverse (SVE.WA)

Executive Summary

Synthaverse S.A. is a Warsaw-based public biotech company that develops and manufactures innovative immunotherapies and biologics, leveraging proprietary technologies. The company operates a dual business model: it markets its own commercial products in oncology and immunoprophylaxis, which provide a stable revenue stream, and offers contract manufacturing services to third parties. This diversified approach positions Synthaverse for sustainable growth, with its established products funding further R&D in advanced therapies. The company's focus on global health and its presence in the immunology space underpin its growth ambitions.

Upcoming Catalysts (preview)

• Q4 2026Regulatory approval for next-generation immunotherapy candidate40% success
• Q2 2027Major contract manufacturing agreement with global pharma55% success
• TBDPositive Phase 2/3 clinical trial results in oncology50% success